Thurston Springer Miller Herd & Titak Inc. Boosts Amgen Inc. Stake

Got story updates? Submit your updates here. ›

Thurston Springer Miller Herd & Titak Inc., an institutional investor, grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 464.5% in the fourth quarter of 2025, according to a recent disclosure with the Securities and Exchange Commission. The firm now owns 4,076 shares of the medical research company's stock, valued at $1,334,000.

Why it matters

This significant increase in Thurston Springer Miller Herd & Titak's Amgen holdings suggests the institutional investor sees strong potential in the biotech company's future performance and growth prospects. Amgen is a major player in the pharmaceutical industry, focused on discovering, developing, and delivering human therapeutics to address serious illnesses.

The details

Thurston Springer Miller Herd & Titak Inc. added 3,354 shares of Amgen to its portfolio during the fourth quarter, bringing its total ownership to 4,076 shares. This represents a 464.5% increase in the firm's Amgen holdings compared to the prior quarter. Amgen is a leading biopharmaceutical company that specializes in the development and commercialization of innovative human therapeutics.

• Thurston Springer Miller Herd & Titak Inc. disclosed its increased Amgen holdings in a filing with the SEC on April 4, 2026.
• The institutional investor's Amgen stake grew by 464.5% in the fourth quarter of 2025 compared to the previous quarter.